Persistence of Severe Pulmonary Hypertension After Transcatheter Aortic Valve Replacement
Authors:
- Luca TestaLuca Testa
- Azeem LatibAzeem Latib
- Federico De MarcoFMFederico De Marco
- Marco De CarloMarco De Carlo
- Claudia FiorinaCFClaudia Fiorina
- Rocco MontoneRMRocco Montone
- Mauro AgnifiliMAMauro Agnifili
- Marco BarbantiMBMarco Barbanti
- Anna Sonia PetronioAPAnna Sonia Petronio
- Giuseppe Biondi ZoccaiGiuseppe Biondi Zoccai
- Federica EttoriFEFederica Ettori
- Silvio KlugmannSKSilvio Klugmann
- 1 June 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 9 (6)
Abstract
Background—: Severe pulmonary hypertension (PH) is considered to negatively affect the outcome after transcatheter aortic valve replacement. However, a clear understanding of the pattern, evolution, and clinical impact of different grades of PH in this setting is lacking. Methods and Results—: A total of 990 consecutive patients were enrolled in 6 high-volume centers and analyzed as follows: group 1, systolic pulmonary artery pressure (sPAP) 60 mm Hg (218 patients; 22%). At 1 month, mortality rate did not differ across the groups. When compared with groups 1 and 2, patients in group 3 had a higher-rate of New York Heart Association 3 to 4 (26% versus 12% and 10%), and a higher-rate of hospitalization for heart failure (7% versus 3% and 3%). At 1 year, when compared with patients in group 1, patients in group 2 and 3 had both a higher overall mortality (hazard ratio [HR], 1.5 [1.3–3.2]; P =0.01 and HR, 2.3 [1.8–2.8]; P =0.001) and a higher cardiac mortality (HR, 1.3 [1.1–2.1]; P =0.01 and HR, 1.7 [1.3–2.5]; P =0.002). After 1 month, the sPAP decreased ≥15 mm Hg in 32% and 35% of the patients in groups 2 and 3. Baseline sPAP >60 mm Hg (HR, 1.6 [1.1–2.3]; P =0.03) and, in a larger extent, a persistent severe PH after 1 month (HR, 2.4 [1.5–2.8]; P =0.004), independently predicted 1-year mortality, whereas the 1-month reduction of the sPAP did not. Conclusions—: The persistence of severe PH after transcatheter aortic valve replacement is a stronger predictor of 1-year mortality than baseline severe PH. The early reduction of sPAP is not associated with a reduced mortality. The benefit of transcatheter aortic valve replacement in terms of quality of life is substantial in patients with and without a reduction of sPAP at early follow-up.Keywords
This publication has 18 references indexed in Scilit:
- Transcatheter Aortic-Valve Replacement with a Self-Expanding ProsthesisNew England Journal of Medicine, 2014
- Transcatheter Aortic Valve Replacement Using a Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at Extreme Risk for SurgeryJACC, 2014
- Prognostic Implications of Pulmonary Hypertension in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve ImplantationCirculation: Cardiovascular Interventions, 2014
- Interplay Between Mitral Regurgitation and Transcatheter Aortic Valve Replacement With the CoreValve Revalving SystemCirculation, 2013
- Clinical Impact of Persistent Left Bundle-Branch Block After Transcatheter Aortic Valve Implantation With CoreValve Revalving SystemCirculation, 2013
- Registry of Transcatheter Aortic-Valve Implantation in High-Risk PatientsNew England Journal of Medicine, 2012
- Transcatheter Valve-in-Valve Implantation Using CoreValve Revalving System for Failed Surgical Aortic BioprosthesesJACC: Cardiovascular Interventions, 2011
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsNew England Journal of Medicine, 2011
- Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo SurgeryNew England Journal of Medicine, 2010
- Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of EchocardiographyJournal of the American Society of Echocardiography, 2010